Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation

Clinical Development Discontinuation and Patient Follow-Up

Updated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion and clinical activity consistent with the Company’s previously reported findings. However, longer-term follow-up did not reflect the level of durability of clinical response the Company believes is needed to support continued development. Following an assessment of the risk-benefit of the therapy, likely enrollment delays and the overall development and potential commercial outlook, Artiva has decided to halt further development of AlloNK. No additional patients will be dosed in any ongoing AlloNK clinical study and the planned Phase 3 pivotal trial will not be initiated. The Company will work closely with the FDA, investigators and institutional review boards to ensure an appropriate and orderly close-out of its clinical development program, including continued safety monitoring and reporting as required.

In light of the decision to discontinue AlloNK development, Artiva no longer plans to present its previously announced clinical data at ACR Convergence 2026 and will cancel its investor webcast scheduled for November 9, 2026. Updated clinical data may be presented at future scientific meetings depending on the outcome of the strategic alternatives process.